Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp
Launched by SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL · Nov 27, 2022
Trial Information
Current as of January 16, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The chromosomal instability (CIN) pathway, the CpG island methylator phenotype (CIMP) pathway and the microsatellite instability (MSI) pathway are three major carcinogenesis pathways to colorectal cancer (CRC). In this study, the investigators aimed to investigate distinctive molecular features of carcinogenesis pathways among healthy control, colorectal adenoma, and CRC and compare their molecular progression according to patients' sex and tumor location as well as disease stage.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Control group: subjects with no evidence of colorectal adenoma or colorectal cancer
- • Colorectal adenoma group: Patients with colorectal adenomas greater than or equal to 10 mm in diameter according to the endoscopic presentation as well as histological validation of colorectal adenoma.
- • Colorectal cancer group: Patients whose biopsy specimen is histologically confirmed as colorectal adenocarcinoma
- Exclusion Criteria:
- • Subjects age under 18 years
- • Previous history of colorectal neoplasms
- • Patients with high bleeding risk or patients who must maintain anti-coagulant or anti-platelet agents
- • Denial to participate in this study
Trial Officials
Nayoung Kim, M.D., Ph.D
Study Chair
Seoul National University Bundang Hospital
About Seoul National University Bundang Hospital
Seoul National University Bundang Hospital is a leading academic medical center located in South Korea, renowned for its commitment to innovative research and excellence in patient care. As a sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields, employing cutting-edge technologies and methodologies to advance healthcare solutions. With a multidisciplinary team of skilled researchers and clinicians, the hospital aims to enhance clinical outcomes through rigorous investigation and collaboration, contributing significantly to the global medical community and improving patient lives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seongnam Si, Gyeonggi Do, Korea, Republic Of
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials